CIK 0002029039
- Non-accelerated filer
- Emerging growth company
Nasus Pharma Ltd
Sign in to watch- Ticker
- NSRX
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- Other
- EIN
- 516022712
- Phone
- +972 542553956
- Business address
- 29 HARAKEVET ST, TEL AVIV - YAFO, Israel, 6618003
- 4 Insider Changes in Ownership
- 6-K Event Nasus Pharma Appoints Nir Sassi as Chief Financial Officer
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Derivatives Options or other derivatives
- S-8 Other Securities Offered to Employees in Benefit Plans
- 6-K Event Report of Foreign Issuer
- 3 Insider Initial Statement of Ownership
- 4 Insider Changes in Ownership
- 424B5 Offering Prospectus
- 6-K Event Report of Foreign Issuer
- 6-K Event Report of Foreign Issuer
- EFFECT Other Notice of Effectiveness
- 6-K Event Report of Foreign Issuer
- F-3 Offering F-3
- EFFECT Other Notice of Effectiveness
- 6-K Event Report of Foreign Issuer
- POS AM Other Post-effective Amendment for Registration Statement
- 6-K Event Report of Foreign Issuer
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 3 Insider Initial Statement of Ownership
Page 1 of 6 · 104 filings